Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial.

MLA

Wu, Yan-Fei, et al. “Immunogenicity Consistency and Safety with Different Production Scales of Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults: A Randomized, Double-Blinded, Immunobridging Trial.” Expert Review of Vaccines, vol. 22, no. 1, Jan. 2023, pp. 662–70. EBSCOhost, https://doi.org/10.1080/14760584.2023.2234997.

APA

Wu, Y.-F., Wei, M.-W., Wang, R.-J., Guo, X.-L., Pan, H.-X., Gao, Y.-C., Li, X.-L., Wang, X., Ma, X.-M., Wan, P., Zhou, L., Zhu, Y.-W., Li, J.-X., & Zhu, F.-C. (2023). Immunogenicity consistency and safety with different production scales of recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults: a randomized, double-blinded, immunobridging trial. Expert Review of Vaccines, 22(1), 662–670. https://doi.org/10.1080/14760584.2023.2234997

Chicago

Wu, Yan-Fei, Ming-Wei Wei, Rui-Jie Wang, Xi-Ling Guo, Hong-Xing Pan, Ya-Chun Gao, Xiao-Long Li, et al. 2023. “Immunogenicity Consistency and Safety with Different Production Scales of Recombinant Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults: A Randomized, Double-Blinded, Immunobridging Trial.” Expert Review of Vaccines 22 (1): 662–70. doi:10.1080/14760584.2023.2234997.